China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk

Dow Jones01-07

0822 GMT - China's healthcare sector will likely get a significant boost from national policies in 1Q, Citi analysts write in a note. This year marks the start of the most positive structural change in the industry, as it will be the first time that China's public healthcare system is able to include commercial insurance providers as significant payers, they say. The brokerage recommends buying shares in companies that will be direct beneficiaries of the reform. These include pharmaceutical and biopharmaceutical firms, pharmaceutical distributors and medical device companies. Citi's top picks include Jiangsu Hengrui Medicine, Hansoh Pharmaceutical, SSY Group, Akeso, Sichuan Kelun-Biotech Biopharmaceutical, Mindray Medical, Sinopharm Group, WuXi AppTec, Wuxi Biologics and Gushengtang. (jiahui.huang@wsj.com; @ivy_jiahuihuang)

(END) Dow Jones Newswires

January 07, 2025 03:23 ET (08:23 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501292221?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 16:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501292221","market":"fut","top_or_hot":-1,"title":"China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0822 GMT - China's healthcare sector will likely get a significant boost from national policies in 1Q, Citi analysts write in a note. This year marks the start of the most positive structural change in the industry, as it will be the first time that China's public healthcare system is able to include commercial insurance providers as significant payers, they say. The brokerage recommends buying shares in companies that will be direct beneficiaries of the reform. These include pharmaceutical and biopharmaceutical firms, pharmaceutical distributors and medical device companies. Citi's top picks include Jiangsu Hengrui Medicine, Hansoh Pharmaceutical, SSY Group, Akeso, Sichuan Kelun-Biotech Biopharmaceutical, Mindray Medical, Sinopharm Group, WuXi AppTec, Wuxi Biologics and Gushengtang. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 07, 2025 03:23 ET (08:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Healthcare Sector to Get Policy Boost in 1Q -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-07 16:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0822 GMT - China's healthcare sector will likely get a significant boost from national policies in 1Q, Citi analysts write in a note. This year marks the start of the most positive structural change ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0039217434.USD","symbol_name":"HSBC GIF CHINESE EQUITY \"AD\" INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2501292221","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501292221","pubTimestamp":1736238180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0822 GMT - China's healthcare sector will likely get a significant boost from national policies in 1Q, Citi analysts write in a note. This year marks the start of the most positive structural change in the industry, as it will be the first time that China's public healthcare system is able to include commercial insurance providers as significant payers, they say. The brokerage recommends buying shares in companies that will be direct beneficiaries of the reform. These include pharmaceutical and biopharmaceutical firms, pharmaceutical distributors and medical device companies. Citi's top picks include Jiangsu Hengrui Medicine, Hansoh Pharmaceutical, SSY Group, Akeso, Sichuan Kelun-Biotech Biopharmaceutical, Mindray Medical, Sinopharm Group, WuXi AppTec, Wuxi Biologics and Gushengtang. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","603259":"药明康德","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","02273":"固生堂","09926":"康方生物","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","BK0188":"融资融券","LU0140636845.USD":"施罗德大中华区股票A Acc","02005":"石四药集团","03692":"翰森制药","02269":"药明生物","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","BK1191":"制药","BK1610":"ETF&股票定投概念","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0196":"行业龙头","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","BK0012":"证金概念","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","01099":"国药控股","SHTDY":"国药控股ADR","BK4137":"综合支持服务","BK1576":"医药外包概念","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","HCSG":"医疗保健服务","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","BK1589":"北水核心资产","LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","LU0052750758.USD":"富兰克林中国基金A Acc","BK1574":"生物医药B类股","BK1583":"高瓴概念","BK1219":"保健护理服务","06990":"科伦博泰生物-B","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD"},"translate_title":"中国医疗保健行业将在第一季度获得政策提振——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9,"603259":0.9,"HCSG":1,"02005":0.9,"SHTDY":0.9,"09926":0.9,"03692":0.9,"01099":0.9,"02269":0.9,"06990":0.9,"02273":0.9},"content_text":"0822 GMT - China's healthcare sector will likely get a significant boost from national policies in 1Q, Citi analysts write in a note. This year marks the start of the most positive structural change in the industry, as it will be the first time that China's public healthcare system is able to include commercial insurance providers as significant payers, they say. The brokerage recommends buying shares in companies that will be direct beneficiaries of the reform. These include pharmaceutical and biopharmaceutical firms, pharmaceutical distributors and medical device companies. Citi's top picks include Jiangsu Hengrui Medicine, Hansoh Pharmaceutical, SSY Group, Akeso, Sichuan Kelun-Biotech Biopharmaceutical, Mindray Medical, Sinopharm Group, WuXi AppTec, Wuxi Biologics and Gushengtang. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2025 03:23 ET (08:23 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501292221"}